We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The effects of extended pre-quit varenicline treatment on smoking behavior and short-term abstinence: a randomized clinical trial.
- Authors
Hawk, L W, Jr; Ashare, R L; Lohnes, S F; Schlienz, N J; Rhodes, J D; Tiffany, S T; Gass, J C; Cummings, K M; Mahoney, M C
- Abstract
Preclinical research and learning theory suggest that a longer duration of varenicline treatment prior to the target quit date (TQD) would reduce smoking rates before cessation and improve abstinence outcomes. A double-blind randomized controlled trial tested this hypothesis in 60 smokers randomized to either an Extended run-in group (4 weeks of pre-TQD varenicline) or a Standard run-in group (3 weeks of placebo, 1 week of pre-TQD varenicline); all the participants received 11 weeks of post-TQD varenicline and brief counseling. During the pre-quit run-in, the reduction in smoking rates was greater in the Extended run-in group than in the Standard run-in group (42% vs. 24%, P < 0.01), and this effect was greater in women than in men (57% vs. 26%, P = 0.001). The rate of continuous abstinence during the final 4 weeks of treatment was higher among women in the Extended group compared to women in the Standard run-in group (67% vs. 35%). Although these data suggest that extension of varenicline treatment reduces smoking during the pre-quit period and may further enhance cessation rates, confirmatory evidence is needed from phase III clinical trials.
- Publication
Clinical pharmacology and therapeutics, 2012, Vol 91, Issue 2, p172
- ISSN
1532-6535
- Publication type
Journal Article
- DOI
10.1038/clpt.2011.317